October 23, 2024 11:26 AM EDT
News Briefing

Ec­co­gene gets $60M from As­traZeneca; Evotec al­so records mile­stone with BMS

ENDPOINTS

Plus, news about DBV, Dou­ble Point Ven­tures and Lu­mos:

Ec­co­gene’s $60M mile­stone from As­traZeneca: The pay­ment ar­rived af­ter Ec­co­gene met sev­er­al …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times